Predictive factors and a corresponding treatment algorithm for controlled ovarian stimulation in patients treated with recombinant human follicle stimulating hormone (follitropin alfa) during assisted reproduction technology (ART) procedures. An analysis of 1378 patients

References

• Inge G, Brinsden P, Elder K. Oocyte number per live birth in IVF: were Steptoe and Edwards less wasteful? Hum Reprod 2004;20(3):588–92
   Google Scholar
• Olivennes F, Ayoubi JM, Fanchin R, et al. GnRH antagonist in single dose application. Hum Reprod Update 2000;6:313–7
   PubMed Web of Science ®Google Scholar
• Howles CM. The place of gonadotrophin-releasing hormone antagonists in reproductive medicine. Reprod Biomed Online 2002;4(Suppl 3):64–71
   PubMedGoogle Scholar
• Popovic-Todorovic B, Loft A, Lindhard A, et al. A prospective study of predictive factors of ovarian response in ‘standard’ IVF/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram. Hum Reprod 2003;18:781–7
   Google Scholar
• Simoni M, Nieschlag E, Gromoll J. Isoforms and single nucleotide polymorphisms of the FSH receptor gene: implications for human reproduction Hum Reprod Update 2002;8: 413–21
   Google Scholar
• Centers for Disease Control. Assisted reproductive technology success rates. National summary and fertility clinics report 2004. US Department of Health and Human Services
   Google Scholar
• Marrs R, Meldrum D, Muasher S, et al. Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reprod Biomed Online 2004;8:175–82
   PubMed Web of Science ®Google Scholar
• Humaidan P. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reprod Biomed Online 2004;8:635–43
   PubMed Web of Science ®Google Scholar
• Klinkert ER, Broekmans FJM, Looman CWN, et al. Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Hum Reprod 2005;20:611–5
   PubMed Web of Science ®Google Scholar
• Fauser BC. Follicle pool depletion: factors involved and implications. Fertil Steril 2000;74:629–30
   PubMed Web of Science ®Google Scholar
• Templeton A, Morris JK. Reducing the risk of multiple births by transfer of two embryos after in vitro fertilization. New Engl J Med 1998;339:573–7
   PubMed Web of Science ®Google Scholar
• Chuang C-C, Chen C-D, Chao K-H, et al. Age is a better predictor of pregnancy potential than basal follicle-stimulating hormone levels in women undergoing in vitro fertilization. Fertil Steril 2003;79:63–8
   Google Scholar
• McClure N, McQuinn B, McDonald J, et al. Body weight, body mass index, and age: predictors of menotropin dose and cycle outcome in polycystic ovarian syndrome? Fertil Steril 1992;58:622–4
   PubMed Web of Science ®Google Scholar
• Imani B, Eijkemans MJC, Faessen GH, et al. Prediction of the individual follicle-stimulating hormone threshold for gonadotropin induction of ovulation in normogonadotropic anovula-tory infertility: an approach to increase safety and efficiency. Fertil Steril 2002;77:83–90
   PubMed Web of Science ®Google Scholar
• Hohmann FP, Laven JSE, De Jong FH, et al. Low-dose exogenous FSH initiated during the early, mid or late follicular phase can induce multiple dominant follicle development. Hum Reprod 2001;16:846–54
   PubMed Web of Science ®Google Scholar
• Pohl M, Hohlagschwandtner M, Obruca A, et al. Number and size of antral follicles as predictive factors in in vitro fertilization and embryo transfer. J Assist Reprod Genet 2000;17:315–8
   PubMed Web of Science ®Google Scholar
• Nahum R, Shifren JL, Chang Y, et al. Antral follicle assessment as a tool for predicting outcome in IVF – is it a better predictor than age and FSH? J Assist Reprod Genet 2001;18:151–5
   PubMed Web of Science ®Google Scholar
• Scheffer GJ, Broekmans FJ, Looman CW, et al. The number of antral follicles in normal women with proven fertility is the best reflection of reproductive age. Hum Reprod 2003;18:700–6
   PubMed Web of Science ®Google Scholar
• Kupesic S, Kurjak A. Predictors of IVF outcome by three-dimensional ultrasound. Hum Reprod 2002;17:950–5
   PubMed Web of Science ®Google Scholar
• Lass A, Skull J, McVeigh E, et al. Measurement of ovarian volume by transvaginal sonography before ovulation induction with human menopausal gonadotrophin for in-vitro fertilization can predict poor response. Hum Reprod 1997;12:294–7
   PubMed Web of Science ®Google Scholar
• Bassil S, Wyns C, Toussaint-Demylle D, et al. The relationship between ovarian vascularity and the duration of stimulation in in-vitro fertilization. Hum Reprod 1997;12:1240–5
   Google Scholar
• Toner JP, Philput CB, Jones GS, et al. Basal follicle-stimulating hormone level is a better predictor of in vitro fertilization performance than age. Fertil Steril 1991;55:784–91
   PubMed Web of Science ®Google Scholar
• Gurgan T, Urman B, Yarali H, et al. Follicle-stimulating hormone levels on cycle day 3 to predict ovarian response in women undergoing controlled ovarian hyperstimulation for in vitro fertilization using a flare-up protocol. Fertil Steril 1997;68:483–7
   PubMed Web of Science ®Google Scholar
• Scott RT, Toner JP, Muasher SJ, et al. Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil Steril 1989;51:651–4
   PubMed Web of Science ®Google Scholar
• Abdalla H, Thum MY. An elevated basal FSH reflects a quantitative rather than qualitative decline of the ovarian reserve. Hum Reprod Update 2004;19:893–8
   Google Scholar
• Fenichel P, Grimaldi M, Olivero JF, et al. Predictive value of hormonal profiles before stimulation for in vitro fertilization. Fertil Steril 1989;51:845–9
   PubMed Web of Science ®Google Scholar
• Bancsi LF, Broekmans FJ, Mol BW, et al. Performance of basal follicle-stimulating hormone in the prediction of poor ovarian response and failure to become pregnant after in vitro fertilization: a meta-analysis. Fertil Steril 2003;79:1091–100
   PubMed Web of Science ®Google Scholar
• Tinkanen H, Blauer M, Laippala P, et al. Prognostic factors in controlled ovarian hyperstimulation. Fertil Steril 1999;72:932–6
   PubMed Web of Science ®Google Scholar
• Fawzy M, Lambert A, Harrison RF, et al. Day 5 inhibin B levels in a treatment cycle are predictive of IVF outcome. Hum Reprod 2002;17:1535–43
   PubMed Web of Science ®Google Scholar
• Bancsi LFJMM, Broekmans FJM, Eijkemans MJC, et al. Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve. Fertil Steril 2002;77:328–36
   PubMed Web of Science ®Google Scholar
• Seifer DB, Lambert-Messerlian G, Hogan JW, et al. Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertil Steril 1997;67:110–4
   PubMed Web of Science ®Google Scholar
• Ficicioglu C, Kutlu T, Demirbasoglu S, et al. The role of inhibin B as a basal determinant of ovarian reserve. Gynecol Endocrinol 2003;17:287–93
   PubMed Web of Science ®Google Scholar
• Eldar-Geva T, Margalioth EJ, Ben-Chetrit A, et al. Serum inhibin B levels measured early during FSH administration for IVF may be of value in predicting the number of oocytes to be retrieved in normal and low responders. Hum Reprod 2002;17:2331–7
   Google Scholar
• Ranieri DM, Quinn F, Makhlouf A, et al. Simultaneous evaluation of basal follicle-stimulating hormone and 17bβ-estradiol response to gonadotropin-releasing hormone analogue stimulation: an improved predictor of ovarian reserve. Fertil Steril 1998;70:227–33
   PubMed Web of Science ®Google Scholar
• Mulders AG, Eijkemans MJ, Imani B, et al. Predictive of chances for success or complications in gonadotrophin ovulation induction in normogonadotrophic anovulatory infertility. Reprod Biomed Online 2003;7:170–8
   PubMedGoogle Scholar
• Yong PYK, Brett S, Baird DT, et al. A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. Fertil Steril 2003;79:308–15
   PubMed Web of Science ®Google Scholar
• Camier B, The French Multicentre Trialists, Howles C M, Truong F. A multicentre, prospective, randomized study to compare a low dose protocol versus conventional administration of recombinant human follicle stimulation hormone (Gonal-F) in normo-responder women undergoing IVF/ICSI. Human reproduction 13 [Abs. Book 1], 1998. p. 159
   Google Scholar
• Out HJ, Lindenberg S, Mikkelsen AL, et al. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation. Hum Reprod 1999;14:622–7
   PubMed Web of Science ®Google Scholar
• Out HJ, David I, Ron-El R, et al. A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles. Hum Reprod 2001;16: 1104–9
   Google Scholar
• Out HJ, Braat DD, Lintsen BME, et al. Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation. Hum Reprod 2000;15:29–35
   PubMed Web of Science ®Google Scholar
• Out HJ, Rutherford A, Fleming R, et al. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Hum Reprod 2004;19:90–5
   PubMed Web of Science ®Google Scholar
• The Latin-American Puregon IVF Study Group. A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro fertilization. Fertil Steril 2001;76:950–6
   PubMed Web of Science ®Google Scholar
• Hohmann FP, Macklon NS, Fauser BC. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist co treatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J Clin Endocrinol Metab 2003;88: 166–73
   Google Scholar
• Driebergen R, Baer G. Quantification of follicle stimulating hormone (follitropin alfa): is in vivo bioassay still relevant in the recombinant age? Curr Med Res Opin 2003;19:41–6
   PubMed Web of Science ®Google Scholar
• Bassett RM, Driebergen R. Continued improvements in the quality and consistency of follitropin alfa, recombinant human FSH. Reprod Biomed Online 2005;10:169–77
   PubMed Web of Science ®Google Scholar
• Hugues JN, Barlow DH, Rosenwaks Z, et al. Improvement in consistency of response to ovarian stimulation with recombinant human follicle stimulating hormone resulting from a new method of calibrating the therapeutic preparation. Reprod Biomed Online 2003;6:185–90
   PubMedGoogle Scholar
• Balasch J, Fabregues F, Penarrubia J, et al. Outcome from consecutive assisted reproduction cycles in patients treated with recombinant follitropin alfa filled-by-bioassay and those treated with recombinant follitropin alfa filled-by-mass. Reprod Biomed Online 2004;8:408–13
   PubMed Web of Science ®Google Scholar
• Yeko T, Pasqualini SR, Alam V, Tredway D. Cumulative ovulation and pregnancy rates according to recombinant human follicle stimulating hormone (r-hFSH) dosing: comparison of a new formulation of follitropin alfa in vials versus the standard formulation of follitropin alfa in ampules. Fertil Steril 2004;82:(Suppl 2);S119
   Google Scholar